Benitec Biopharma to Participate in the Citizens JMP Life Science ConferenceGlobeNewswireMay 01, 2024HAYWARD, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) ("Benitec" or the "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary "Silence and Replace" DNA-directed RNA interference ("ddRNAi") platform, today announced that members of Benitec management will participate in Citizens JMP Life Science Conference, taking place in New York, NY from May 13-14, 2024.
Presentation Details:Date: May 13, 2024Time: 11:00 am EDTPresenter: Jerel Banks, MD, PhD, Executive Chairman and Chief Executive Officer
The Benitec presentation will also be available via live webcast here.
Please contact your Citizens JMP representative to schedule a 1x1 meeting with Benitec management.
AboutBenitecBiopharmaInc.
Benitec Biopharma Inc. ("Benitec" or the "Company") is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines with headquarters in Hayward, California. The proprietary "Silence and Replace" DNA-directed RNA interference platform combines RNA interference, or RNAi, with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The Company is developing Silence and Replace-based therapeutics for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy (OPMD). A comprehensive overview of the Company can be found on Benitec's website at www.benitec.com.
InvestorRelationsContact:
Irina KofflerLifeSci AdvisorsTel: (917) 734-7387ikoffler@lifesciadvisors.com
COMTEX_451713030/2010/2024-05-01T08:00:37
HAYWARD, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) ("Benitec" or the "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary "Silence and Replace" DNA-directed RNA interference ("ddRNAi") platform, today announced that members of Benitec management will participate in Citizens JMP Life Science Conference, taking place in New York, NY from May 13-14, 2024.
Presentation Details:Date: May 13, 2024Time: 11:00 am EDTPresenter: Jerel Banks, MD, PhD, Executive Chairman and Chief Executive Officer
The Benitec presentation will also be available via live webcast here.
Please contact your Citizens JMP representative to schedule a 1x1 meeting with Benitec management.
AboutBenitecBiopharmaInc.
Benitec Biopharma Inc. ("Benitec" or the "Company") is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines with headquarters in Hayward, California. The proprietary "Silence and Replace" DNA-directed RNA interference platform combines RNA interference, or RNAi, with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The Company is developing Silence and Replace-based therapeutics for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy (OPMD). A comprehensive overview of the Company can be found on Benitec's website at www.benitec.com.
InvestorRelationsContact:
Irina KofflerLifeSci AdvisorsTel: (917) 734-7387ikoffler@lifesciadvisors.com
COMTEX_451713030/2010/2024-05-01T08:00:37
7.01% $0.62
